mirvetuximab soravtansine (Elahere) Report issue

Biologics mAb ADC Orphan Drug FDA Approved FDA First in Class Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.   Wikipedia

Chemistry

More Chemistry

Pharmacology

Alternative names

imgn853 | imgn-853 | mirvetuximab soravtansine

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (4)


 

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms (approved 2022)

Ovarian Neoplasms (approved 2022)

Peritoneal Neoplasms (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Biomarkers (Phase 2)

BRCA1 Protein (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 3)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Fallopian Tubes (Phase 2)

Hamartoma (Phase 3)

Mutation (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 3)

Uterine Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue